AU2022218787A1 - INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS - Google Patents

INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS Download PDF

Info

Publication number
AU2022218787A1
AU2022218787A1 AU2022218787A AU2022218787A AU2022218787A1 AU 2022218787 A1 AU2022218787 A1 AU 2022218787A1 AU 2022218787 A AU2022218787 A AU 2022218787A AU 2022218787 A AU2022218787 A AU 2022218787A AU 2022218787 A1 AU2022218787 A1 AU 2022218787A1
Authority
AU
Australia
Prior art keywords
alkyl
pyrimidin
carboxylic acid
methylbenzofuro
pyrrolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022218787A
Other languages
English (en)
Inventor
Matthew Boxer
Meera Kumar
Robert G. Lowery
David Maloney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BellBrook Labs LLC
Original Assignee
BellBrook Labs LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BellBrook Labs LLC filed Critical BellBrook Labs LLC
Publication of AU2022218787A1 publication Critical patent/AU2022218787A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2022218787A 2021-02-11 2022-02-11 INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS Abandoned AU2022218787A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148201P 2021-02-11 2021-02-11
US63/148,201 2021-02-11
PCT/US2022/016073 WO2022174012A1 (en) 2021-02-11 2022-02-11 INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS

Publications (1)

Publication Number Publication Date
AU2022218787A1 true AU2022218787A1 (en) 2023-08-17

Family

ID=82837325

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022218787A Abandoned AU2022218787A1 (en) 2021-02-11 2022-02-11 INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS

Country Status (8)

Country Link
US (1) US20240174684A1 (https=)
EP (1) EP4291188A4 (https=)
JP (1) JP2024506904A (https=)
KR (1) KR20230144550A (https=)
CN (1) CN116997339A (https=)
AU (1) AU2022218787A1 (https=)
CA (1) CA3206520A1 (https=)
WO (1) WO2022174012A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119119063A (zh) 2021-05-12 2024-12-13 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物
WO2022238335A1 (en) * 2021-05-12 2022-11-17 Boehringer Ingelheim International Gmbh Pyridine derivatives with c-linked cyclic substituents as cgas inhibitors
JP2025528113A (ja) * 2022-08-10 2025-08-26 ベルブルック ラボズ，エルエルシー 治療剤としてのｃＧＡＳ活性の阻害剤
KR20250103719A (ko) * 2022-11-09 2025-07-07 베링거 인겔하임 인터내셔날 게엠베하 cGAS 억제제로서의 사이클릭 벤즈이미다졸 유도체
AU2023376006A1 (en) * 2022-11-09 2025-03-13 Boehringer Ingelheim International Gmbh Cyclic pyridine derivatives as cgas inhibitors
WO2025233174A1 (en) 2024-05-08 2025-11-13 Boehringer Ingelheim International Gmbh Benzimidazole derivatives as cgas inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090028819A (ko) * 2006-07-11 2009-03-19 얀센 파마슈티카 엔.브이. 히스타민 ｈ４ 수용체의 벤조푸로- 및 벤조티에노피리미딘 조절제
WO2008074445A1 (en) * 2006-12-18 2008-06-26 Ucb Pharma, S.A. Novel tricyclic and heterotricyclic derivatives, processes for preparing them, pharmaceutical compositions thereof
WO2013115167A1 (ja) * 2012-01-31 2013-08-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 アムバチニブ誘導体
EP3565810A1 (en) * 2017-01-03 2019-11-13 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
CA3125625A1 (en) * 2019-01-04 2020-07-09 Bellbrook Labs, Llc Inhibitors of cgas activity as therapeutic agents

Also Published As

Publication number Publication date
WO2022174012A1 (en) 2022-08-18
JP2024506904A (ja) 2024-02-15
KR20230144550A (ko) 2023-10-16
EP4291188A1 (en) 2023-12-20
US20240174684A1 (en) 2024-05-30
EP4291188A4 (en) 2025-01-08
CA3206520A1 (en) 2022-08-18
CN116997339A (zh) 2023-11-03

Similar Documents

Publication Publication Date Title
US20240174684A1 (en) INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS
AU2021345111B2 (en) Indole derivatives as Ras inhibitors in the treatment of cancer
CN115873020B (zh) Ras抑制剂
JP7443495B2 (ja) ヘテロ環式ｒｉｐ１キナーゼ阻害剤
AU2019220632B2 (en) IRAK degraders and uses thereof
CA3159561A1 (en) Ras inhibitors
US11337970B2 (en) Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP6804524B2 (ja) Ｉｒａｋ４モジュレーターとしての二環式縮合ヘテロアリールまたはアリール化合物
EP3889145B1 (en) 8-cyano-5-piperidino-quinolines as tlr7/8 antagonists and their uses for treating immune disorders
AU2005212409C1 (en) Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors
CN107614499B (zh) 吡啶并［3，4-d］嘧啶衍生物及其药学上可允许的盐
CA3123869A1 (en) Compounds that participate in cooperative binding and uses thereof
JP2023541236A (ja) Ｓｈｐ２変異を有する悪性腫瘍を治療するためのｓｏｓ１阻害剤の使用
IL323654A (en) Macrocyclic ras inhibitors
IL323653A (en) Macrocyclic ras inhibitors
IL272016B2 (en) Pyrrolidine derivatives and their use as tlr7/8 antagonists
KR20190112000A (ko) Rho-키나아제 억제제로서 티로신 아마이드 유도체
CN115916194A (zh) 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
AU2018385693A1 (en) Antibody construct-drug conjugate for the treatment of hepatitis
KR20210112316A (ko) 치료제로서의 cgas 활성 억제제
JP2018505166A (ja) Ｉｒａｋ阻害剤としてのピリダジノン大環状化合物及びその使用
JP7049519B2 (ja) 治療用複素環式化合物
CN115279765B (zh) 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
WO2024054602A1 (en) Heterobifunctional compounds and methods of treating disease
JP2025528113A (ja) 治療剤としてのｃＧＡＳ活性の阻害剤

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period